361 related articles for article (PubMed ID: 31587329)
1. Targeting MDM2 for novel molecular therapy: Beyond oncology.
Wang W; Qin JJ; Rajaei M; Li X; Yu X; Hunt C; Zhang R
Med Res Rev; 2020 May; 40(3):856-880. PubMed ID: 31587329
[TBL] [Abstract][Full Text] [Related]
2. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases.
Thomasova D; Mulay SR; Bruns H; Anders HJ
Neoplasia; 2012 Dec; 14(12):1097-101. PubMed ID: 23308042
[TBL] [Abstract][Full Text] [Related]
3. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
5. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
6. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
7. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy.
Wang W; Zafar A; Rajaei M; Zhang R
Cells; 2020 May; 9(5):. PubMed ID: 32397368
[TBL] [Abstract][Full Text] [Related]
8. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
Narain S; Berman N; Furie R
Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
[TBL] [Abstract][Full Text] [Related]
9. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
10. Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.
Shaikh MF; Morano WF; Lee J; Gleeson E; Babcock BD; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2016 Dec; 46(6):627-634. PubMed ID: 27993876
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
12. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
13. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
15. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
16. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
17. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
19. MDM2 beyond cancer: podoptosis, development, inflammation, and tissue regeneration.
Ebrahim M; Mulay SR; Anders HJ; Thomasova D
Histol Histopathol; 2015 Nov; 30(11):1271-82. PubMed ID: 26062755
[TBL] [Abstract][Full Text] [Related]
20. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.
Qin JJ; Wang W; Zhang R
Prog Mol Biol Transl Sci; 2017; 151():195-216. PubMed ID: 29096894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]